Targeting Tumors with KRAS G12C Mutations with Adagrasib (MRTX849): Current Status & Future Questions

Time: 10:00 am
day: Day One

Details:

  • History of targeting KRAS in the clinic and recent advancements to directly target KRAS G12C
  • Clinical progress of KRAS G12C inhibitors (eg, adagrasib) in the clinic
  • Future questions and directions for targeting KRAS G12C

Speakers: